glp 1 agonist tirzepatide SEMA vs TIRZ vs RETA — the 3 GLP-1s everyone's comparing, side by side. Save this one. 🧬 The whole thing comes down to one idea: how many receptors each drug pulls Effects of tirzepatide, a dual

Meanwhile, lawmakers in Louisiana are debating whether to allow Medicaid to cover GLP-1s for obesity treatment if enrollees have another chronic condition, or comorbidity, such as prediabetes, hypertension or cardiovascular disease

Where semaglutide targets only the GLP-1 receptor, tirzepatide also activates the GIP receptor (glucose-dependent insulinotropic polypeptide)

To maximize results, choose liposomal versions of both to ensure they survive the digestive process

However, BPC 157 is a therapeutic agent not approved by the FDA, which cites risk of immunogenicity, peptide-related impurities, and limited safety-related information as reasons for banning BPC-157